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1. Introduction 
Tricuspid aortic valve is a flexible membrane that opens and closes 100,000 times a day (Fig. 
1) [1].  
 
 
 
 
Fig. 1. Normal tricuspid aortic valve in closed and open position. 
Aortic stenosis is the most common valvular lesion in Europe and North America [2]. As 
incidence of acute rheumatic fever has declined, calcific aortic stenosis (CAS) has become 
the most common indication for surgical valve replacement in the United States (Fig. 2) [3].  
Regarding population aged>65 years, its incidence is 2-7% [2]. Interestingly, aortic sclerosis 
(aortic valve calcification without hemodynamic compromise) is present in more than 25% 
of patients older than age 65 years [5]. 
Recent studies provide evidence that atherosclerosis and CAS share common features in 
relation to risk factors and histopathologic lesions [3]. Moreover, histopathologic evidence 
suggests that early lesions in CAS are not just a result secondary to aging, but an active 
cellular process. Recent research implies  that the classical “response to injury hypothesis”, 
initially described in atherosclerosis, seems to represent the cornerstone of pathophysiology 
[4]. 
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Fig. 2. Causes of aortic valve stenosis. 
2. Anatomy - histology 
Aortic valve is normally tricuspid, although in 1% of the population it is found to be 
congenitally bicuspid. 
The internal collagen framework of the leaflets is arranged in three layers: fibrosa, spongiosa 
and ventricularis. 
Fibrosa with its dense connective tissue provides strength, spongiosa with its loose matrix of 
glycoproteins provides a cushion for the mechanical forces, and ventricularis provides 
elasticity for changes of shape during opening and closing [6]. 
All three layers of aortic valve are avascular and are innervated by adrenergic and 
cholinergic neural networks [6].  
In aortic sclerosis and stenosis, calcified nodules are initially observed at the base of the 
cusps and their presence is gradually extended towards the orifice. All three cusps are 
usually affected but one or more may be dominant. Heavy calcification is associated with 
hemodynamic impairment leading ultimately to need for valve replacement [7]. 
3. Calcific aortic stenosis (CAS) and atherosclerosis 
3.1 Risk factors 
Several studies suggest that traditional risk factors for atherosclerosis such as male gender, 
hypertension, dyslipidemia and renal failure are implicated in pathogenesis of CAS (Fig. 3) 
[2, 3, 8]. 
In addition, as we will discuss later, histologic lesions of CAS and atherosclerosis share 
common features. Inflammatory infiltration, lipid accumulation, cellular apoptosis and 
profileration and remodeling of extracellular matrix are present in both situations. Genetic  
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Fig. 3. Risk factors for calcific aortic stenosis. 
polymorphisms and activation of certain pathways such as renin-angiotensin system seem 
to play vital role and elucidation of their participation in pathophysiology of CAS comprises 
major challenge [2, 6]. 
3.2 Similarities in histopathology 
CAS and atherosclerosis present characteristic lesions with fibromyxomatous degeneration, 
inflammatory infiltration and lipid accumulation. Mechanical forces play significant role in 
progression of lesions [9].  
However, pattern of disease is more diffuse in CAS in relation to atherosclerosis where lesions 
are characterized by necrotic core and fibrous cap. In addition, calcification is more prominent 
in aortic cusps and is observed even in early stages of pathophysiologic process [6]. 
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Neoangiosis comprises, also, a common feature in CAS and atherosclerosis. Nevertheless, 
there are some differences. Normal valves are avascular in contrast to artery wall which is 
supplied by vasa vasorum. New vessels in atherosclerotic lesions are, actually, branches of 
vasa vasorum and present some defective characteristics as their wall is thin and friable 
resulting very often in intraplaque hemorrhage. Angiogenesis in calcified valves is not 
completely understood but it seems to be more organized. Several growth factors such as 
VEGF (vascular endothelial growth factor) are implicated in formation of vessels which have 
developed interendothelial junctions and partial basement membrane – like structures [10-12]. 
4. Pathophysiology of Calcific aortic stenosis (CAS) 
Several factors lead to activation of endothelium with subsequent expression of significant 
factors such as cytokines and adhesion molecules. Subendothelial accumulation of lipids 
and inflammatory cells comprise the early lesions which trigger a “response to injury”. This 
phase includes remodeling of extracellular matrix and transformation of quiescent valvular 
interstititial cells to activated interstitial cells (VICs) that consequently gain osteoblastic 
phenotype (Fig. 4). 
 
 
Fig. 4. Schematic illustration of pathophysiology of calcific aortic stenosis (ox-LDL: oxidized 
LDL, ang II: angiotensin II, qVIC: quiescent valvular interstitial cell, aVIC: activated valvular 
interstitial cell). 
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Expression of bone regulatory factors is related to formation of calcified nodules, lesions 
which represent later stages of aortic stenosis [8].  
We will discuss further in detail all aspects of pathophysiologic process. 
4.1 Endothelium 
Abnormal activation of aortic valve endothelium was observed initially in experimental 
hypercholesterolemia rabbits [3]. 
Recent research has shown increased E-selectin plasma levels in patients with severe CAS 
which normalize after aortic valve surgery [13,14]. In addition, high levels of endothelial 
microparticles have been found in these patients. Endothelial microparticles are small 
vesicles that consist of a plasma membrane surrounding a small amount of cytosol. The 
membrane of the endothelial microparticle contains specific receptors and cell surface 
molecules which enable the identification of the endothelial origin of the microparticle. 
Inflammatory infiltration in calcified aortic valves has been related to circulating levels of 
endothelial microparticles [13, 15]. Several endothelial markers such as CD31, CD34, von 
Willebrand factor, and CEACAM1 (carcinoembryonic antigen-related cell adhesion 
molecule) were markedly expressed in tissue samples of human aortic valves that were 
from patients undergoing valve replacement for severe calcific, non-rheumatic aortic 
stenosis [13].  
Remarkably, decreased availability of nitric oxide and prostacyclin was noticed in these 
specimen. These molecules are considered to be major modulators of inflammatory 
processes [1]. 
4.2 Valvular Interstitial Cells (VICs) 
Valve integrity is determined by extracellular matrix. Moreover, quality and quantity of 
extracellular matrix components are depended on function of VICs [16]. 
Not surprisingly, age – related reduction of this cellular population  is accompanied by 
fibrous degeneration [17]. 
VICs are elongated, spindle – like cells and most of them are located in fibrosa. They display 
morphological and functional characteristics of fibroblasts, smooth muscle cells and 
myofibroblasts [17].  
Five distinct phenotypes of VICs have been recognized: 
1. Embryonic progenitor endothelial/mesenchymal VICs 
2. Quiescent VICs 
3. Activated VICs 
4. Adult progenitor VICs 
5. Osteoblastic VICs 
These cells present plasticity and are capable of changing their phenotype under certain 
circumstances (Fig. 5) [18].  
VICs preserve stability and integrity of the valves and are involved in synthesis and 
remodeling of extracellular matrix [17].   
Calcified nodules consist of nonviable myofibroblasts and crystals of hydroxyapatite. 
Viable osteoblast-like cells surround these structures expressing bone regulatory proteins. 
Alkaline phosphatase constitutes unquestionable proof of bone formation in areas of 
tissue injury [1]. 
www.intechopen.com
 
Aortic Stenosis – Etiology, Pathophysiology and Treatment 
 
38
 
Fig. 5. Subtypes of Valvular Interstitial Cells. 
VICs resemble to vascular smooth muscle cells (VSMCs) but their embryology is different. 
VSMCs derive from cardiac neural crest and lateral mesoderm-derived mesenchyme [6]. 
Myocardin-related transcription factor-B is the master regulator of  differentiation of VSMCs 
that originate from the neural crest [19]. On the other hand, endothelial to mesenchymal 
transformation (EMT)  phenomenon is considered to be responsible for the origin of VICs. 
The process seems to be  regulated by TGF-ǃ (transforming growth factor-ǃ), NOTCH1, and 
Wnt/ǃ-catenin signals [20]. 
4.3 Mechanical forces 
Aortic valve cusps are subjected to unceasing influence of severe mechanical forces during 
lifetime. It is believed that the attachment area of the aortic leaflets to the aortic root  
encounters the strongest mechanical influence, which may provoke endothelial dysfunction. 
As we aforementioned,  activation of endothelium is related to expression of adhesion 
molecules and cytokines that initiate several pathophysiologic processes [3]. 
Leucocyte infiltration and lipid accumulation take place initiating tissue injury with reactive 
fibro-proliferative changes. Alteration of valve morphology leads to further increase of local 
shear stress and ultimately a vicious circle is set up [13]. 
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Preliminary studies suggested the ‘wear and tear’ theory in order to underline significance 
of mechanical stress in pathogenesis of aortic stenosis [4]. 
However, mechanical stress does not necessarily hold primary role in pathogenesis. 
Genetically predisposed individuals in atherosclerosis and aortic valve sclerosis are very 
prone to mechanical forces that trigger effortlessly key molecular signaling pathways in 
both diseases [13]. 
4.4 Genetic influence 
4.4.1 Inhibitory proteins 
Activation of signaling pathways is depended on expression of inhibitory proteins. Recent 
evidence has shown that BMP (bone morphogenetic protein), a major bone regulator, is 
inhibited by several proteins such as noggin, chordin, follistatin, gremlin and Smad proteins. 
Relative deficiency of these factors could be responsible for aortic valve ossification [1]. 
4.4.2 Lipoproteins 
Determination of allelic variants of lipoproteins in patients suffering from aortic stenosis 
comprises an interesting research topic. Although a higher prevalence of apoE2 [21] and 
apoE4 [22], has been observed in some studies, these results have not been affirmed by other 
researchers.  
4.4.3 Inflammatory factors 
Inflammation is a prerequisite for aortic valve calcification. Specific genetic variants may 
trigger intense immune response with devastating results. Polymorphisms of the 
interleukin-10 gene promoter as well as simultaneous presence of the rare chemochine 
receptor 5 and connective tissue growth factor alleles are associated with severe calcium 
burden in patients with aortic stenosis [13]. 
4.4.4 Bone metabolism  
Regarding bone metabolism genomics,  vitamin D receptor genetic polymorphism has been 
extensively investigated [23]. High incidence of the B allele has been found in aortic stenosis 
and is related with reduced calcium absorption, bone resorption and increased expression of 
parathormone [3, 13]. 
Runx2, also designated Cbfa1, belongs to the Runt domain family and is the master 
transcription factor for bone formation inducing transcription of osteoblast-related genes 
that enhance mineralization such as osteocalcin gene [24]. Trancriptional activity of Runx2 
may be suppresed by Notch1 signaling. Recent research demonstrated that a nonsense 
mutation of the NOTCH1 gene is associated with enhanced calcium deposition in aortic 
valves probably via reduced inhibition of Runx2 expression [25].  
Finally, a polymorphism of the alpha estrogen receptor, in post-menopausal women is 
related to increase of cholesterol levels and predisposition to aortic valve calcification [26].  
4.4.5 Cell cycle proteins 
Finally, some cell cycle regulatory proteins are considered to participate in pathophysiologic 
process. P21WAF1/CIP1 (cyclin-dependent proteinkinase inhibitor p21), and 14-3-3 belong to 
this category and their expression is reduced in areas of calcification [27]. 
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4.5 Bone factors 
Osteoblastic phenotype of VICs implies expression of bone proteins exhibiting regulatory or 
structural role. 
Recent evidence suggests that aortic valve calcification is an active process involving 
chondro-osteogenic pathways. Calcified nodules are composed of hydroxyapatite crystals 
precipitated on a matrix of collagen, osteopontin (OP) and osteocalcin (OC) [3]. 
Aortic VICs in areas containing calcific deposits show significantly higher expression of bone 
regulatory factors such as BMP, Runx2, Osterix in relation to non-calcified areas (Fig. 6) [3,24]. 
 
 
Fig. 6. Runx2 and Osterix immunoreactivity in normal and stenotic aortic valves (x400). 
Sox9, a critical regulator of both early and late stages of chondrogenesis, is overexpressed in 
stenotic aortic valves [24]. 
Several lines of evidence suggest an important role of the OPG (osteoprotegerin)/RANKL 
(receptor activator of nuclear factor NF-κB ligand)/RANK (receptor activator of nuclear 
factor NF-κB) axis in valve pathology [28, 29]. Specifically, in cultured human aortic valve 
myofibroblasts, RANKL promotes calcium deposition in extracellular matrix and enhances 
the expression of osteoblast-related genes, promoting osteoblastic phenotype [30]. 
This phenotype of interstitial cells was also found to be related with high levels of Toll-like 
receptors (TLR) 2 and 4. Activation of these receptors may lead to increased expression of 
cytokines and osteogenic factors such as BMP-2 and Runx2 [31]. 
4.6 Lipids  
Initially, Otto et al. noted the association of lipid metabolism with CAS. Accumulation of 
intracellular and extracellular lipids was constant finding in pathologic specimens [32]. 
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Involvement of the Lrp5 receptor (low-density lipoprotein receptor-related protein 5) in 
valve calcification has been implicated in several studies [3]. 
LRP5/Wnt signaling pathway has great importance in bone remodeling. Wnt3a protein is 
secreted by endothelial cells and has the ability to bind to LDL receptor-related proteins 
LRP5 or LRP6 complex on the myofibroblast extracellular membrane [33]. This signal results 
in cytoplasmic accumulation of catenin which subsequently enters nucleus and interacts 
with proteins of the T-cell factor/lymphoid-enhancer factor-1 family affecting expression of 
target genes such as cyclin D, Runx2, and Sox9 (Fig. 7). 
 
 
Fig. 7. Effects of LRP5/Wnt signaling pathway on gene expression. 
The role of lipid signaling of the LRP5 receptor has been investigated in experimental 
models of vascular atherosclerosis. Relative deficiency of LRP5 is associated with reduction 
of intracellular ATP and calcium in response to glucose and thereby decreasing glucose-
induced insulin secretion [8]. Interestingly, another study suggested that experimental 
hypercholesterolemia leads to increased LRP5 receptor expression which promotes cell 
proliferation and extracellular matrix remodeling. Mineralization, finally, ensues and 
progressive aortic stenosis is developed [8]. In addition, LRP5 plays significant role in the 
differentiation process of aortic VICs into osteoblasts, providing another link between lipid 
metabolism and aortic valve calcification [34]. 
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A high total cholesterol/HDL ratio and small circulating LDL particles (<255A°) seem to be 
independently associated with rapid development of aortic sclerosis and stenosis.  
High levels of angiotensin converting enzyme have been observed in valve lesions 
presenting increased LDL and apolipoprotein B concentration. It is speculated that plasma 
lipoproteins promote retention of  angiotensin converting enzyme [13, 35]. 
4.7 Renin-angiotensin system 
As we aforementioned, intense angiotensin-converting enzyme localization was observed in 
fibromyxomatous lesions. Lisinopril managed to attenuate presence of angiotensin-
converting enzyme in experimental models [36]. Members of the renin-angiotensin system 
are implicated in mechanisms of repair of the aortic valve as a normal response to injury. 
However, hyperactivation of the renin-angiotensin system exerts deleterious effects leading 
to pathologic fibrosis [1]. 
4.8 Hemostasis 
Role of hemostasis has not been fully elucitaded in CAS. Increased levels of von Willebrand 
factor as well as expression of fibrinolysis and platelet markers may be just a consequence of 
pathophysiologic process [13]. 
4.9 Neoangiosis 
Several studies have confirmed  neovessel formation in calcified valves [11, 37]. 
Angiogenesis may be implicated in calcification process by various ways including 
recruitment of inflammatory cells, transdifferentiation of pericytes of neovessel wall and 
secretion of cytokines from activated endothelial cells [24]. 
The whole process is related with increased levels of endothelial nitric oxide synthase, 
SPARC protein (secreted protein, acidic and rich in cysteine/osteonectin), VEGF and its 
receptors Flt-1 and Flk-1 [13]. VEGF-A exerts  chemotactic activity for human monocytes via 
its receptor Flt-1, and also promotes their activation and migration [4]. 
Notably, low grade lesions are characterized by greater neoangiosis relatively to severe 
lesions suggesting a temporal pattern of the phenomenon in development of aortic stenosis 
[37]. 
Considering the fact that neoangiosis is characterized by a short time window as it takes 
place in days or months, potent therapeutic intervention must be timely and targeted [13]. 
4.10 Extracellular matrix remodeling  
Recent studies have shown overexpression of elastolytic cathepsins S, K, and V and their 
inhibitor cystatin C in stenotic aortic valves [3]. 
Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases that are capable of 
degrading all kinds of extracellular matrix proteins, but also can process a number of 
bioactive molecules. Several studies have demonstrated implication of MMP-1, MMP-3, 
MMP-9 in aortic stenosis [9, 38, 39]. In addition, MMP-1 colocalizes with TNF-a suggesting 
an association between extracellular matrix remodeling and inflammation [9]. Regarding 
MMP-2, there is no evidence so far for a potential involvement in progression of disease 
[40].  
It is well known that MMPs activity is depended on their respective tissue inhibitors 
(TIMPs). There is much confusion about role of TIMPs in pathophysiology of aortic stenosis. 
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As previous studies [9, 41] have shown conflicting results, further research is needed in 
order to unravel a possible connection with valve remodeling. 
Except MMPs, several other factors with degrading activity such as cathepsins S, K and V 
overwhelm  calcified lesions. Cathepsin S expression is more prominent in severely calcified 
areas while cathepsin V is related to endothelial cells [42]. Moreover, colocalization of 
cathepsin G and TGF-1b in mast cells lends further support to hypothesis that inflammation 
is the underlying cause of calcification [43]. 
Another extracellular matrix glycoprotein, tenascin-C, presents abundant expression in 
calcified valves. Tenascin-C is a highly conserved, multifunctional protein implicated in cell 
proliferation, migration, differentiation, and apoptosis [44]. Emerging evidence suggests that 
tenascin-C enchances alkaline phosphatase activity and expression of MMPs promoting 
calcium deposition in degenerative lesions. In contrast, normal valves are deficient or 
present very low levels of tenascin C [1, 4]. 
Upregulation of cystatin C, a cysteine protease inhibitor, has been found in calcific human 
aortic valves. Its presence must not be considered circumstantial as previous study reported 
increased expression  in mature osteoblasts [45]. 
Extracellular matrix proteins with lytic activity may exert favorable effects in a normal 
repair process. Nevertheless, overexpression of these factors or defective inhibitory 
mechanisms are responsible for valve injury [4]. 
4.11 Inflammation 
Inflammation is considered to be the most significant aspect of pathophysiologic process. 
Several inflammatory mediators have been observed in diseased valves such as terminal 
complement complex C5b-9, IL-1b, IL-6, IL-8, TNF-ǂ (tumor necrosis factor-ǂ) and Heat 
Shock Protein-60 [13]. 
In addition, high serum levels of soluble endothelial adhesion molecules have been found in 
patients with severe aortic stenosis who had no history of coronary artery disease. 
Intercellular adhesion molecule-1, vascular cell adhesion molecule-1 and E-selectin are 
characteristic representatives indicating an ongoing inflammatory response [4].  
There is also intense expression of TGF-b1 [13] which binds to specific proteins of 
extracellular matrix. Lytic activity of MMPs induces release of TGF-ǃ1 which in turn 
promotes cellular migration and aggregation as well as apoptosis of VICs [1, 46]. 
TLR on interstitial cells seem to play critical role in inflammatory response. In vitro studies 
have demonstrated that peptidoglycan or lipopolysaccharide stimulation of TLR activates 
NF-kB pathway with subsequent expression of cytokines and bone – related factors [47]. 
In addition, recent research has shown that aortic VICs in areas containing calcific deposits 
showed significantly higher Osterix and NFATc1 nuclear immunolocalization compared to 
non-calcified fibrocellular regions. NFATc1 is a member of a multigene family of 
transcription factors that belong to the Rel group and control T lymphocyte activation and 
differentiation [24]. 
Therefore, inflammation and osteogenesis are indissolubly related. 
4.12 Oxidative stress 
Oxidative stress has been implicated in aortic stenosis as several research projects have 
confirmed increase in reactive oxygen species, and a reduction in the expression and activity 
of antioxidant enzymes catalase and NADPH [48]. 
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4.13 Infectious agents 
Great effort has been made by several researchers in order to relate infectious agents with 
aortic stenosis but data are conflicting.  
Bratos-Perez et al. studied aortic valve specimens collected at surgery and indicated the 
presence of nanobacteria, growing self-replicating calcifying nanoparticles, that potentially 
represent new pathogens. Their expression has been noticed already in carotid disease and 
abdominal aorta aneurysms [49]. 
Nevertheless, role of infectious microorganisms has not been clarified and further evidence 
is needed. 
4.14 Autonomic nervous system 
Aortic valve is innervated by adrenergic and cholinergic neural networks. Upregulation of 
b-adrenergic receptors, especially b2, was observed in areas of calcifcation [50]. In addition, 
a stable analogue of the purinergic receptor P2Y (ATP-g-S) may cause the 
transdifferentiation of cultured interstitial aortic valve cells into osteoblasts [51]. 
5. Treatment effects on pathophysiologic mechanisms 
Study of effects of therapeutic strategies on progression of aortic stenosis has provided 
significant evidence regarding pathophysiology of disease. 
5.1 Statins 
Role of statins has been studied extensively but findings are inconsistent in patients with 
moderate to severe degrees of aortic stenosis [13]. 
Atorvastatin was shown to attenuate leucocyte infiltration and expression of bone 
regulatory factors in aortic valves of experimental models with hypercholesterolemia [3]. 
These effects are attributed to modulation of Lrp5 pathway [30] and endothelial nitric oxide 
synthase [52]. 
Previous reports suggest that expression of MMPs, in particular MMP-1, MMP-2, MMP-3, 
and MMP-9, is reduced by VICs and macrophages under the effect of statin treatment [1]. 
As we aforementioned, TGF-ǃ is an important regulator of cellular proliferation and 
differentiation and modulator of inflammation and extracellular matrix remodelling. Statins 
exhibit variable effects on TGF-ǃ expression in aortic valves. Several studies provide evidence 
that levels of TGF-ǃ in human VICs are reduced with implementation of statin treatment in 
initial stages of disease [53]. This results in attenuated presence of ALP (alkaline phosphatase) 
and osteocalcin in calcified lesions [53]. However, these findings were not confirmed in late 
stages of disease indicating the narrow therapeutic time window of statins [54].  
Atorvastatin extenuates the activity of alkaline phosphatase in cultured interstitial aortic 
cells [48] in contrast to bone tissue where it exerts opposite effect. [55]. Statins, also, reduce 
the expression of RGS (regulators of G protein-mediated signaling) proteins in calcified 
valves triggering activation of extracellular-regulated kinases [56] that enhance proliferation 
of myofibroblasts [13]. Increased expression of BMP-2, a major osteogenic stimulus. has 
been observed in experimental models treated with HMG-CoA reductase inhibitors [54]. 
These contradictory findings, called ‘statin paradox’, suggest that beneficial impact could be 
time-depended and beyond this time window statins exhibit neutral or even harmful effect. 
A possible explanation is that different cell populations prevail during several stages of 
pathophysiologic process resulting in variable response to statin treatment. This could be 
www.intechopen.com
 
Pathophysiologic Mechanisms of Age – Related Aortic Valve Calcification 
 
45 
related to the results of several trials that failed to demonstrate positive therapeutic effects 
[13]. In SALTIRE (Scottish Aortic Stenosis and Lipid Lowering Trial, Impact on Regression) 
and SEAS (simvastatin and ezetimibe in aortic stenosis study) studies, statin therapy had no 
effect on the rate of progression of aortic stenosis. Further projects such as ASTRONOMER 
(Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin) trial are under 
way to try to define the role of statins in pathophysiologic process. Meanwhile, there is no 
indication for statin use specific to aortic stenosis [4]. 
In conclusion, statins exhibit pleiotropic activities and their role must be further analyzed. 
Inhibition of the HMG-CoA reductase influences not only cholesterol synthesis but also 
biosynthesis of isoprenoid compounds that are implicated in inflammation and osteogenesis 
[13]. 
5.2 Angiotensin Converting Enzyme Inhibitors (ACEI) 
As we discussed earlier, angiotensin converting enzyme exhibits intense presence in 
diseased valves and there is much evidence regarding its involvement in pathophysiology. 
Preliminary reports suggest that olmesartan, an angiotensin type 1 receptor antagonist, 
preserves endothelial integrity and inhibits transdifferentiation of VICs into myofibroblasts 
or osteoblasts [58]. 
5.3 Smoking cessation 
Smoking, the single most preventable cause of death in Western World, is a leading risk 
factor not only for atherosclerosis but also for aortic stenosis. Tobacco components, mostly 
nicotine and acetaldehyde, have the ability to induce TGF-b1 expression in cultured 
fibroblasts and mast cell activation. These effects are enough to cause increased collagen 
burden favoring valve calcification [13]. 
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